autologous genetically modified afpc332 t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 8, 2017 (NCT03132792)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetImmunity, passive
Immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous genetically modified afpc332 t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06515314 | Phase 1 | Aug 10, 2024 | Government of China, HRYZ Biotech Co. |
| NCT03971747 | Phase 1 | Jun 30, 2019 | Cellular Biomedicine Group Ltd., Fudan University |
| NCT03132792 | Phase 1 | May 8, 2017 | Adaptimmune, University of California, Los Angeles |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptimmune | For profit | 1 | 1 | 1 | 2017 |
| Cellular Biomedicine Group Ltd. | For profit | 1 | 1 | 1 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| HRYZ Biotech Co. | For profit | 1 | 1 | 1 | 2024 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1